Adaptive
Stock
Stock
Ticker: ADPT
ADPT
Price
Price
CHART BY
Frequently asked questions
What is Adaptive's market capitalization?
The market capitalization of Adaptive is $3.83B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Adaptive?
Adaptive's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.408. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Adaptive's stock?
Currently, 9 analysts cover Adaptive's stock, with a consensus target price of $29.81. Analyst ratings provide insights into the stock's expected performance.
What is Adaptive's revenue over the trailing twelve months?
Over the trailing twelve months, Adaptive reported a revenue of $308.08M.
What is the EBITDA for Adaptive?
Adaptive's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$20.26M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Adaptive?
Adaptive has a free cash flow of -$24.03M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Adaptive have, and what sector and industry does it belong to?
Adaptive employs approximately 624 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Adaptive's shares?
The free float of Adaptive is 154.87M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.83B
- EPS (TTM)
- -$0.408
- Free Float
- 154.87M
- Revenue (TTM)
- $308.08M
- EBITDA (TTM)
- -$20.26M
- Free Cashflow (TTM)
- -$24.03M
Pricing
- 1D span
- $23.86$24.90
- 52W span
- $12.00$30.74
Analyst Ratings
The price target is $29.81 and the stock is covered by 9 analysts.
Buy
8
Hold
1
Sell
0
Information
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
- Employees
- 624
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- ADPT
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet